Selected Publications
Mamtani R, Tsingas K, Parikh RB, Elsouda D, Mucha L, Fuldeore R, Hubbard RA: Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer Urol Oncol 42 (6): 2024.
Wang LS, Hubbard RA, Mamtani R.:
Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade Pharmacoepidemiol Drug Saf. 33 (5): 2024.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw 22 (4): 2024.
Rosenberg JE*, Mamtani R*, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Sridhar SS, Pappot H, Gurney H, Bedke J, van der Heijden MS, Galli L, Keam B, Masumori N, Meran J, O'Donnell PH, Park SH, Grande E, Sengeløv L, Uemura H, Skaltsa K, Campbell M, Matsangou M, Wu C, Hepp Z, McKay C, Powles T, Petrylak DP.: Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy Eur Urol 85 (6): 2024.
Bange EM, Li Y, Kumar P, Doucette A, Gabriel P, Parikh R, Li EH, Mamtani R*, Getz KD*.: The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer Cancer 130 (4): 2024.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horwitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial Nat Med 29 (11): 2023.
Bange EM, Li Y, Kumar P, Doucette A, Gabriel P, Parikh R, Li EH, Mamtani R*, Getz KD*.: The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer Cancer 10.1002/cncr.35116. : 2023.
Boursi B, Wileyto EP, Mamtani R, Domchek SM, Golan T, Hood R, Reiss KA.: Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival JAMA Netw Open : 2023.
Doshi GK, Li H, Burcu M, Annavarapu S, Wells K, Imai K, Moreno BH, Singhal P, Mamtani R.: Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma. Front Oncol : 2023.
Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME.: Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens Clin Lung Cancer 24 (6): 2023.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia,
PA
19147
Phone: 215-662-7606
Patient appointments: 800-789-7366